Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: Disclosing the importance of side-chain and backbone functionalities

Journal of Medicinal Chemistry

Volumn 50, Issue 2, 2007, Pages 192-198

  Ueda, Satoshi ^a   Oishi, Shinya ^a   Wang, Zi Xuan ^b   Araki, Takanobu ^a   Tamamura, Hirokazu ^a,c   Cluzeau, Jérôme ^a   Ohno, Hiroaki ^a   Kusano, Shuichi ^d   Nakashima, Hideki ^d   Trent, John O ^e   Peiper, Stephen C ^b   Fujii, Nobutaka ^a  

^a KYOTO UNIVERSITY   (Japan)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 NAPHTHYL)ALANINE; ALANINE; ALLYL COMPOUND; AMINO ACID; ARGININE; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOPEPTIDE; DEXTRO ALANINE; DEXTRO ARGININE; FUNCTIONAL GROUP; GLYCINE; METHYL GROUP; NAPHTHYL GROUP; NITROGEN; PENTAPEPTIDE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CHIRALITY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EPIMER; METHYLATION; NUCLEAR MAGNETIC RESONANCE; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ALANINE; ANIMALS; CRICETINAE; CRICETULUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PEPTIDES, CYCLIC; RADIOLIGAND ASSAY; RECEPTORS, CXCR4; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846430034     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0607350     Document Type: Article

References (39)

1. Murphy, P. M.; Baggiolini, M.; Charo I. F.; Herbert, C. A.; Horuk, R.; Matsushima, K.; Miller, L. H.; Oppenheim, J. J.; Power, C. A. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 2000, 52, 145-176.
2. Mackay, C. R.; Chemokines: immunology's high impact factors. Nat. Immunol. 2001, 2, 95-101.
3. Premack, B. A.; Schall, T. J. Chemokine receptors: gateways to inflammation and infection. Nat. Med. 1996, 2, 1174-1178.
4. Zlotnik, K.; Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12, 121-127.
5. Bleul, C. C.; Fuhlbrigge, R. C.; Casanovas, J. M.; Aiuti, A.; Springer, T. A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 1996, 2, 1101-1109.
6. Tachibana, K.; Hirota, S.; Iizasa, H.; Yoshida, H.; Kawabata, K.; Kataoka, Y.; Kitamura, Y.; Matsushima, K.; Yoshida, N.; Nishikawa, S.; Kishimoto, T.; Nagasawa, T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393, 591-594.
7. Nagasawa, T.; Hirota, S.; Tachibana, K.; Takakura, N.; Nishikawa, S.; Kitamura, Y.; Yoshida, N.; Kikutani, H.; Kishimoto, T. Defects of B-cell limphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382, 635-638.
8. + progenitors to peripheral blood. J. Exp. Med. 1997, 2, 111-120.
9. Zhu, Y.; Yu, Y.; Zhang, X. C.; Nagasawa, T.; Wu, J. Y.; Rao, Y. Role of the chemokine SDF-1 as the meningeal attractant for embryonic cerebellar neurons. Nat. Neurosci. 2002, 5, 719-720.
10. Stumm, R. K.; Zhou, C.; Ara, T.; Lazarini, F.; Dubois-Dalcq, M.; Nagasawa, T.; Hollt, V.; Schulz, S. CXCR4 regulates interneuron migration in the developing neocortex. J. Neurosci. 2003, 23, 5123-5130.
11. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry co-factor: Functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996, 272, 872-877.
12. Oberlin, E.; Amara, A.; Bachelerie, F.; Bessia, C.; Virelizier, J. L.; Arenzana-Seisdedos, F.; Schwartz, O.; Heard, J. M.; Clark-Lewis, I.; Legier, D. L.; Loetscher, M.; Baggiolini, M.; Moser, B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382, 833-835.
13. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; Mcclanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. M.; Barrera, J. L.; Mohar, A.; Verástegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56.
14. + T cell accumulation in rheumatoid arthritis synovium. J. Immunol. 2000, 165, 6590-6598.
15. 7]-polyphemusin II). Biochem. Biophys. Res. Commun. 1992, 189, 845-850.
16. Tamamura, H.; Xu, Y.; Hattori, T.; Zhang, X.; Arakaki, R.; Kanbara, K.; Omagari, A.; Otaka, A.; Ibuka, T.; Yamamoto, N.; Nakashima, H.; Fujii, N. A low molecular weight inhibitor against the chemokine redeptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. 1998, 255, 877-882.
17. Tamamura, H.; Hori, A.; Kanzaki, N.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. T140 analogues as CXCR4 antagonists identified as anti-metastatic agent in the treatment of breast cancer. FEBS Lett. 2003, 550, 79-83.
18. Takenaga, M.; Tamamura, H.; Hiramatsu, K.; Nakamura, N.; Yamaguchi, Y.; Kitagawa, A.; Kawai, S.; Nakashima, H.; Fujii, N.; Igarashi, R. A single treatment with microcapsules containing a CXCR4 antagonist suppressed pulmonary metastasis of murine melanoma. Biochem. Biophys. Res. Commun. 2004, 320, 226-232.
19. Tamamura, H.; Fujisawa, M.; Hiramatsu, K.; Mizumoto, M.; Nakashima, H.; Yamamoto, N.; Otaka, A.; Fujii, N. Identification of a CXCR4 antagonist, T140 analog, as anti-rheumatoid arthritis agent. FEBS Lett. 2004, 569, 99-104.
20. Schols, D.; Struyf, S.; Van Damme, J.; Este, J. A.; Henson, G.; De Clarcq, E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 1997, 186, 1383-1388.
21. Donzella, G. A.; Schols, D.; Lin, S. W.; Este, J. A.; Nagashima, K. A.; Maddon P. J. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 1998, 4, 72-76.
22. Ichiya, K.; Yokoyama-Kumakura, S.; Tanaka, Y.; Tanaka, R.; Hirose, K.; Bannai, K.; Edamatsu, T.; Yanaka, M.; Niitani, Y.; Miyano-Kurosaki, N.; Takaku, H.; Koyanagi, Y.; Yamamoto, N. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4185-4190.
23. Fujii, N.; Oishi, S.; Hiramatsu, K.; Araki, T.; Ueda, S.; Tamamura, H.; Otaka, A.; Kusano, S.; Terakubo, S.; Nakashima, H.; Broach, J. A.; Trent, J. O.; Wang, Z.; Peiper, S. C. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angew. Chem. Int. Ed. 2003, 42, 3251-3253.
24. Tamamura, H.; Omagari, A.; Oishi, S.; Kanamoto, T.; Yamamoto, N.; Peiper, S. C.; Nakashima, H.; Otaka, A.; Fujii, N. Pharmacophore identification of a specific CXCR4 inhibitor, T140, lead to development of effective anti-HIV agents with very high selectivity indexes. Bioorg. Med. Chem. Lett. 2000, 10, 2633-2637.
25. Tamamura, H.; Hiramatsu, K.; Ueda, S.; Wang, Z.; Kusano, S.; Terakubo, S.; Trent, J. O.; Peiper, S. C.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. Stereoselective synthesis of [L-Arg-L/ D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J. Med. Chem. 2005, 48, 380-391.
26. Tamamura, H.; Esaka, A.; Ogawa, T.; Araki, T.; Ueda, S.; Wang, Z.; Trent, J. O.; Tsutsumi, H.; Masuno, H.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Otaka, A.; Fujii, N. Structure-activity relationship studies on CXCR4 antagonists having cyclic pentapeptide scaffolds. Org. Biomol. Chem. 2005, 3, 4392-4394.
27. Tamamura, H.; Araki, T.; Ueda, S.; Wang, Z.; Oishi, S.; Esaka, A.; Trent, J. O.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Otaka. A.; Fujii, N. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J. Med. Chem. 2005, 48, 3280-3289.
28. Marshall, G. R.; Wu, Y.; Heyden, N. V.; Ratner, L.; Nikiforovich, G. V. Backbone modification of cyclic pentapeptide antagonist of CXCR4. In Peptides 2004 (Proceedings of 3rd international and 28th European peptide symposium); Flegel, M., Fridkin, M., Gilon, C., Slaninova, J., Eds.; Kenes International: Switzerland, 2005; pp 748-749.
29. Miller, S. C.; Scanlan, T. S. Site-selective N-methylation of peptides on solid support. J. Am. Chem. Soc. 1997, 119, 2301-2302.
30. Lin, X.; Dorr, H.; Nuss, J. M. Utilization of Fukuyama's sulfonamide protecting group for the synthesis of N-substituted α-amino acids and derivatives. Tetrahedron Lett. 2000, 41, 3309-3313.
31. Carpino, L. A.; 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. J. Am. Chem. Soc. 1993, 115, 4397-4398.
32. Bollhagen, R.; Schmiedberger, M.; Barlos, K.; Grell, E. A new reagent for the cleavage of fully protected peptides synthesised on 2-chlorotrityl chloride resin. J. Chem. Soc., Chem. Commun. 1994, 2559-2560.
33. 3 integrin for a new cancer therapy. Angew. Chem. Int. Ed. Engl. 1997, 36, 1374-1389.
34. Toniolo, C. Conformationally restricted peptides through short range cyclization. Int. J. Pept. Protein Res. 1990, 35, 287-300.
35. 3 integrin antagonists. J. Med. Chem. 1998, 42, 3033-3040.
36. Rajeswaran, W. G.; Hocart, S. J.; Murphy, W. A.; Taylor, J. E.; Coy, D. H. Highly potent and subtype selective ligand derived by N-methyl scan of a somatostatin antagonist. J. Med. Chem. 2001, 44, 1305-1311.
37. α-Methylated Scan. J. Med. Chem. 2005, 48, 507-514.
38. 2 amide bond. Since backbone conformation and side chain disposition of cu-conformer of 32 was apparently different from the parent peptides 2 and 3, we assumed that the major trans-conformer could contribute to the bioactivities of 32, although contribution of the minor cis-conformer cannot be ruled out.
39. Navenot, J. M.; Wang, Z. X.; Trent, J. O.; Murray, J. L.; Hu, Q. X.; DeLeeuw, L.; Moore, P. S.; Chang, Y.; Peiper, S. C. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins; Differences in primary structural requirements for RANTES. MIP-1α, and vMIP-II binding. J. Mol. Biol. 2001, 39, 380-393.